Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Expands By 150.0%

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 24,819 shares, an increase of 150.0% from the July 15th total of 9,927 shares. Approximately 1.2% of the company’s stock are sold short. Based on an average trading volume of 319,914 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Biodexa Pharmaceuticals stock. Sabby Management LLC bought a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals comprises about 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 10th largest position. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Price Performance

BDRX stock opened at $1.52 on Friday. Biodexa Pharmaceuticals has a twelve month low of $1.02 and a twelve month high of $59.40. The firm has a 50 day simple moving average of $2.30 and a 200-day simple moving average of $3.79.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Biodexa Pharmaceuticals presently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.